MARKET

RCKT

RCKT

ROCKET PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.58
+3.72
+7.17%
After Hours: 55.58 0 0.00% 16:51 02/26 EST
OPEN
51.94
PREV CLOSE
51.86
HIGH
56.25
LOW
50.04
VOLUME
490.05K
TURNOVER
--
52 WEEK HIGH
67.48
52 WEEK LOW
9.01
MARKET CAP
3.36B
P/E (TTM)
-30.5754
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
WestRock Co. stock outperforms competitors despite losses on the day
Shares of WestRock Co. slid 1.40% to $43.59 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...
marketwatch.com · 2d ago
Rocket Pharmaceuticals (RCKT) Receives a Hold from Oppenheimer
SmarterAnalyst · 2d ago
WestRock Co. stock outperforms market despite losses on the day
Shares of WestRock Co. slipped 1.47% to $44.21 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...
marketwatch.com · 3d ago
Rocket Pharmaceuticals (RCKT) Receives a Buy from Needham
Needham analyst Gil Blum assigned a Buy rating to Rocket Pharmaceuticals (RCKT) today and set a price target of $75.00. The company's shares closed last
SmarterAnalyst · 3d ago
BRIEF-Rocket Pharmaceuticals Reports Q4 And Full Year 2020 Financial And Operational Results
reuters.com · 3d ago
Rocket Pharmaceuticals EPS misses by $0.57
Rocket Pharmaceuticals (RCKT): Q4 GAAP EPS of -$1.08 misses by $0.57.Cash position. As of December 31, 2020, we had cash, cash equivalents and investments of $482.7 million. Rocket expects such
Seekingalpha · 3d ago
Rocket Pharmaceuticals Q4 EPS $(1.08) Down From $(0.39) YoY
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(1.08) per share. This is a 176.92 percent decrease over losses of $(0.39) per share from the same period last year.
Benzinga · 3d ago
Rocket Pharmaceuticals Expects Resources Will Be Sufficient to Fund Its Ops Into 2H of 2023 >RCKT
Rocket Pharmaceuticals Expects Resources Will Be Sufficient to Fund Its Ops Into 2H of 2023 >RCKT
Dow Jones · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCKT. Analyze the recent business situations of ROCKET PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RCKT stock price target is 70.91 with a high estimate of 100.00 and a low estimate of 56.00.
EPS
Institutional Holdings
Institutions: 221
Institutional Holdings: 66.97M
% Owned: 110.62%
Shares Outstanding: 60.54M
TypeInstitutionsShares
Increased
51
7.19M
New
66
3.16M
Decreased
48
3.45M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Roderick Wong
President/Chief Executive Officer/Director
Gaurav Shah
Chief Financial Officer
Carlos Garcia-Parada
Chief Operating Officer
Kinnari Patel
Senior Vice President - Finance
Kamran Alam
Chief Accounting Officer/Vice President - Finance/Controller/Treasurer
John Militello
Other
Jonathan Schwartz
Director
David Southwell
Independent Director
Elisabeth Bjork
Independent Director
Carsten Boess
Independent Director
Pedro Granadillo
Independent Director
Gotham Makker
Independent Director
Naveen Yalamanchi
  • Dividends
  • Splits
  • Insider Activity
No Data
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.